Allogene Therapeutics Inc (ALLO) stock saw a decline, ending the day at $2.16 which represents a decrease of $-0.04 or -1.82% from the prior close of $2.2. The stock opened at $2.21 and touched a low ...

ALLO Fiber has announced construction will soon begin this spring on a network build in the city of Boulder, Colorado.

Allo.xyz, a platform specializing in real-world asset (RWA) tokenization and lending, has secured a landmark $100 million ...

UAE-based Allo.xyz, a platform for real-world asset (RWA) tokenization and lending, has secured a $100 million Bitcoin-backed ...

Addressing the $900 trillion real-world asset opportunity, Allo continues to pioneer tokenization solutions that seamlessly ...

Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Oppenheimer has recently resumed Allogene Therapeutics Inc (ALLO) stock to Outperform rating, as announced on August 8, 2024, according to Finviz. Earlier, on May 31, 2024, Piper Sandler had initiated ...

ALLO Fiber is pleased to announce its fiber broadband network build of the City of Boulder, CO. ALLO anticipates construction ...

Allo Communications LLC, a Lincoln, Nebraska-based telecommunications company, plans to build a fiber-optic broadband network ...

The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approved for ...